Cadrenal Therapeutics Inc. is closing in on seeking U.S. Food and Drug Administration approval for its anticoagulant drug called tecarfarin, needing to complete one Phase III trial for the drug.
“We have a strong plan to complete the trial as well as commercialize the product,” CEO Quang Pham said in a June 12 streaming presentation to the Emerging Growth Conference.
Subscribe today. Cancel anytime.